Adverse Skin Effects of Imatinib, a Tyrosine Kinase Inhibitor
Authors:
- M. Pretel-IrazabalMPM. Pretel-Irazabal
- A. Tuneu-VallsATA. Tuneu-Valls
- N. Ormaechea-PérezNON. Ormaechea-Pérez
Open Access
- 1 September 2014
- journal article
- Published by Elsevier in Actas Dermo-Sifiliograficas
- Vol. 105 (7) , 655-662
Abstract
No abstract availableThis publication has 64 references indexed in Scilit:
- Pityriasis rosea-like Drug Eruption Induced by Imatinib Mesylate (Gleevec™)Annals of Dermatology, 2011
- T-regulatory cell response in psoriasis and changes with imatinib therapyClinical and Experimental Dermatology, 2009
- Management of imatinib‐related exacerbation of psoriasis in a patient with a gastrointestinal stromal tumourAustralasian Journal of Dermatology, 2009
- Exacerbation of psoriasis in a chronic myelogenous leukemia patient treated with imatinibThe Journal of Dermatology, 2007
- Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid LeukemiaNew England Journal of Medicine, 2006
- Desensitization to imatinib in patients with leukemiaAnnals of Allergy, Asthma & Immunology, 2006
- Pityriasis rosea–like eruption during treatment with imatinib mesylate: Description of 3 casesJournal of the American Academy of Dermatology, 2005
- Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trialThe Lancet, 2004
- The Role of Kit‐Ligand in Melanocyte Development and Epidermal HomeostasisPigment Cell Research, 2003
- Imatinib treatment: Specific issues related to safety, fertility, and pregnancySeminars in Hematology, 2003